Risk Factors Affecting Breast Cancer-Related Lymphedema: Serial Body Weight Change During Neoadjuvant Anthracycline Plus Cyclophosphamide Followed by Taxane

Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2017.06.003
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Risk Factors and Management of Breast Cancer-Related Lymphedema

International Journal of Medicine
2015English

Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer (Registration Number: ChiCTR1900023052)

Scientific Reports
Multidisciplinary
2019English

Body Mass Index and Breast Cancer Treatment-Related Lymphedema

Supportive Care in Cancer
Oncology
2011English

Neoadjuvant Eribulin Mesylate Following Anthracycline and Taxane in Triple Negative Breast Cancer: Results From the HOPE Study

PLoS ONE
Multidisciplinary
2019English

Neoadjuvant 5-Fluorouracil, Epirubicin and Cyclophosphamide Chemotherapy Followed by Docetaxel in Refractory Patients With Locally Advanced Breast Cancer

Oncology Reports
MedicineCancer ResearchOncology
2007English

Epirubicin/Cyclophosphamide Followed by Docetaxel as Primary Systemic Therapy in Breast Cancer

Annals of Cancer Research and Therapy
Cancer ResearchOncologyPharmacology
2014English

Risk Factors and Prediction Model for Persistent Breast-Cancer-Related Lymphedema: A 5-Year Cohort Study

Supportive Care in Cancer
Oncology
2018English

Evolving Approaches to Metastatic Breast Cancer Patients Pre-Treated With Anthracycline and Taxane

BioDrugs
MedicineBiotechnologyPharmacology
2013English

Factors Associated With Professional Healthcare Advice Seeking in Breast Cancer-Related Lymphedema

Journal of Surgical Oncology
MedicineSurgeryOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy